Rivaroxaban

In those with non-valvular atrial fibrillation it appears to be as effective as warfarin in preventing nonhemorrhagic strokes and embolic events.rivaroxaban is associated with lower rates of serious and fatal bleeding events than warfarin though rivaroxaban is associated with higher rates of bleeding in the gastrointestinal tract. In july 2012, the uk´s national institute for health and clinical excellence recommended rivaroxaban to prevent and treat venous thromboembolism